JP2013531029A5 - - Google Patents

Download PDF

Info

Publication number
JP2013531029A5
JP2013531029A5 JP2013519185A JP2013519185A JP2013531029A5 JP 2013531029 A5 JP2013531029 A5 JP 2013531029A5 JP 2013519185 A JP2013519185 A JP 2013519185A JP 2013519185 A JP2013519185 A JP 2013519185A JP 2013531029 A5 JP2013531029 A5 JP 2013531029A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
het
linked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013519185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013531029A (ja
JP5860045B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2011/052920 external-priority patent/WO2012004714A2/en
Publication of JP2013531029A publication Critical patent/JP2013531029A/ja
Publication of JP2013531029A5 publication Critical patent/JP2013531029A5/ja
Application granted granted Critical
Publication of JP5860045B2 publication Critical patent/JP5860045B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013519185A 2010-07-09 2011-07-01 化合物 Expired - Fee Related JP5860045B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36291910P 2010-07-09 2010-07-09
US61/362,919 2010-07-09
PCT/IB2011/052920 WO2012004714A2 (en) 2010-07-09 2011-07-01 Chemical compounds

Publications (3)

Publication Number Publication Date
JP2013531029A JP2013531029A (ja) 2013-08-01
JP2013531029A5 true JP2013531029A5 (enExample) 2014-07-24
JP5860045B2 JP5860045B2 (ja) 2016-02-16

Family

ID=44504012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013519185A Expired - Fee Related JP5860045B2 (ja) 2010-07-09 2011-07-01 化合物

Country Status (6)

Country Link
US (1) US9096558B2 (enExample)
EP (1) EP2590957B1 (enExample)
JP (1) JP5860045B2 (enExample)
CA (1) CA2803118C (enExample)
ES (1) ES2526675T3 (enExample)
WO (1) WO2012004714A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2855019A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Biaryl ether sulfonamides and their use as therapeutic agents
MX2014005297A (es) 2011-10-31 2014-09-11 Xenon Pharmaceuticals Inc Compuestos de bencenosulfonamida y su uso como agentes terapeuticos.
US8889741B2 (en) 2012-02-09 2014-11-18 Daiichi Sankyo Company, Limited Cycloalkane derivatives
CN104718188B (zh) 2012-05-22 2018-08-21 基因泰克公司 N-取代的苯甲酰胺类及其在治疗疼痛中的用途
MX2015000164A (es) 2012-07-06 2015-08-12 Genentech Inc Benzamidas n-sustituidas y metodos para usarlas.
CN104718205B (zh) * 2012-10-15 2017-12-01 株式会社大熊制药 钠通道阻滞剂、其制备方法和其用途
CA2891056A1 (en) 2012-10-26 2014-05-01 Merck Sharp & Dohme Corp. N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels
TW201418242A (zh) 2012-10-26 2014-05-16 Du Pont 作為除草劑之經取代的三唑
CL2012003253A1 (es) * 2012-11-22 2013-01-11 Univ Concepcion Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico.
UA112028C2 (uk) * 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
CA2905613C (en) * 2013-03-14 2017-11-28 Daiichi Sankyo Company, Limited Drug for respiratory diseases
EP2968280A4 (en) 2013-03-14 2016-08-10 Genentech Inc SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
KR20150131254A (ko) 2013-03-15 2015-11-24 크로모셀 코포레이션 통증 치료를 위한 소듐 채널 조절자
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2015038533A2 (en) 2013-09-10 2015-03-19 Chromocell Corporation Sodium channel modulators for the treatment of pain and diabetes
US20160339099A1 (en) * 2013-09-16 2016-11-24 Ucl Business Plc Synergistic combination of analgesic drugs
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
JP2017516803A (ja) 2014-05-30 2017-06-22 ファイザー・インク ナトリウムチャネル阻害剤として有用なベンゼンスルホンアミド
US10005724B2 (en) 2014-07-07 2018-06-26 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
JP2018520107A (ja) 2015-05-22 2018-07-26 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
EP3341353A1 (en) 2015-08-27 2018-07-04 Genentech, Inc. Therapeutic compounds and methods of use thereof
CR20180242A (es) 2015-09-28 2018-08-10 Genentech Inc Compuestos terapéuticos y sus métodos de uso
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
TW201726637A (zh) 2015-12-18 2017-08-01 默沙東藥廠 對電位閘控鈉通道具選擇活性之羥基烷基胺－及羥基環烷基胺－取代之二胺－芳基磺胺化合物
WO2017172802A1 (en) 2016-03-30 2017-10-05 Genentech, Inc. Substituted benzamides and methods of use thereof
RU2019114964A (ru) 2016-10-17 2020-11-17 Дженентек, Инк. Терапевтические средства и способы их применения
US10793550B2 (en) 2017-03-24 2020-10-06 Genentech, Inc. 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
WO2019165290A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Pyridine-sulfonamide compounds and their use against pain and related conditions
EP3774801A1 (en) 2018-03-30 2021-02-17 F. Hoffmann-La Roche AG Fused ring hydro-pyrido compounds as sodium channel inhibitors
WO2019217822A1 (en) * 2018-05-11 2019-11-14 Chromocell Corporation Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2020117626A1 (en) 2018-12-05 2020-06-11 Merck Sharp & Dohme Corp. 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels
WO2020248123A1 (en) 2019-06-11 2020-12-17 Merck Sharp & Dohme Corp. Hydroxypyrrolidine-substituted arylsulfonamide compounds with selective activity in voltage-gated sodium channels

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6284923B1 (en) 1997-08-22 2001-09-04 Tularik Inc Substituted benzene compounds as antiproliferative and cholesterol lowering action
EP0967201A1 (en) 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
CA2349180A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett Anthranilic acid derivatives
ES2208364T3 (es) 1999-07-16 2004-06-16 Warner-Lambert Company Llc Procedimiento para tratar dolor cronico usando inhibidores de mek.
WO2002089793A1 (en) 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
WO2002089785A1 (en) 2001-05-07 2002-11-14 Smithkline Beecham Corporation Sulfonamides
PL366619A1 (en) 2001-05-11 2005-02-07 Biovitrum Ab Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
JP2003081937A (ja) 2001-09-07 2003-03-19 Bayer Ag ベンゼンスルホンアミド誘導体
AU2003273762A1 (en) 2002-10-28 2004-05-13 Novo Nordisk A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
AU2003295408A1 (en) 2002-11-06 2004-06-03 Smithkline Beecham Corporation Sulfonamides
WO2004043917A1 (en) 2002-11-06 2004-05-27 Smithkline Beecham Corporation Sulfonamides
TW200418831A (en) 2002-11-06 2004-10-01 Smithkline Beecham Corp Sulfonamides
EP1997495B1 (en) 2003-03-24 2013-01-02 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfanyl-benzenesulfonamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
AR045238A1 (es) * 2003-08-08 2005-10-19 Vertex Pharma Compuestos utiles como inhibidores de canales ionicos regulados por voltaje
DE10344223A1 (de) 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
CA2606254A1 (en) 2005-05-06 2006-11-16 Pfizer Limited .beta.-amino acid derivatives
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
US8030487B2 (en) 2006-07-07 2011-10-04 Targegen, Inc. 2-amino—5-substituted pyrimidine inhibitors
GEP20125425B (en) 2006-10-18 2012-03-26 Pfizer Prod Inc Biaryl ether urea compounds
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
US9422235B2 (en) 2006-12-19 2016-08-23 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
US7687522B2 (en) 2006-12-20 2010-03-30 Amgen Inc. Substituted pyridines and pyrimidines and their use in treatment of cancer
EP1953141A1 (en) 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Aryl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
CL2008000835A1 (es) 2007-03-23 2008-10-03 Icagen Inc Pfizer Ltd Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm
AP2516A (en) 2007-05-03 2012-11-26 Pfizer Ltd 2-Pyridine carboxamide derivatives as sodium channel modulators
WO2009012242A2 (en) * 2007-07-13 2009-01-22 Icagen, Inc. Sodium channel inhibitors
BRPI0822240A2 (pt) 2007-12-21 2015-06-30 Wyeth Llc Composto imidazo [1,2-b] piridazina como moduladores de receptores x hepáticos
BRPI0822239A2 (pt) 2007-12-21 2015-06-30 Wyeth Llc Composto de pirazolo[1,5-a] pirimidina
BRPI0822237A2 (pt) 2007-12-21 2015-06-30 Wyeth Llc Compostos de imidazo [1,2-a] piridina
JP2012509334A (ja) 2008-11-19 2012-04-19 ワイス・エルエルシー 肝ｘ受容体（ｌｘｒ）モジュレーターとしての極性キナゾリン類
HRP20150355T1 (hr) 2009-01-12 2015-06-19 Pfizer Limited Sulfonamidni derivati
CA2804593C (en) 2010-07-09 2015-11-24 Pfizer Limited Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2804716A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
EP2593432B1 (en) 2010-07-12 2014-10-22 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
WO2012007869A2 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds

Similar Documents

Publication Publication Date Title
JP2013531029A5 (enExample)
JP2013531031A5 (enExample)
JP2016505619A5 (enExample)
JP2016506960A5 (enExample)
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение
JP2016536363A5 (enExample)
TN2012000608A1 (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
RU2016118399A (ru) Производные 4-аминометилбензойной кислоты
RU2016125306A (ru) Новые пестицидные соединения и применения
JP2014525420A5 (enExample)
JP2015501833A5 (enExample)
JP2016536364A5 (enExample)
JO3811B1 (ar) مركبات غير متجانسة حلقياً ثلاثية الحلقات ملتحمة تعمل في صورة مثبطات انزيم إنتيجراز hiv
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
GB201201744D0 (en) Novel compounds
JP2012528166A5 (enExample)
JP2013537203A5 (enExample)
RU2013116924A (ru) N1/n2-лактамные ингибиторы ацетил-коа-карбоксилаз
MX347616B (es) Inhibidores de csf-1r para el tratamiento de tumores de cerebro.
CR20200418A (es) Inhibidores de orginasa y sus mètodos de uso antecedentes
JP2013063968A5 (enExample)
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
JP2014510147A5 (enExample)
EA201590022A1 (ru) Новые производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса
AR082218A1 (es) Derivados de arilamida que tienen propiedades antiandrogenicas y proceso de preparacion